Abstract
Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.
| Original language | English |
|---|---|
| Pages (from-to) | 29-34 |
| Number of pages | 6 |
| Journal | Giornale Italiano di Dermatologia e Venereologia |
| Volume | 142 |
| Issue number | 1 |
| Publication status | Published - 2007 |
Fingerprint
Keywords
- Dermatitis, atopic
- Desloratadine
- Histamine H1 antagonists
ASJC Scopus subject areas
- Dermatology
Cite this
Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis. / Ayala, Fabrizio; Balato, N.; Gaudiello, F.; Ayala, Fabio.
In: Giornale Italiano di Dermatologia e Venereologia, Vol. 142, No. 1, 2007, p. 29-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis
AU - Ayala, Fabrizio
AU - Balato, N.
AU - Gaudiello, F.
AU - Ayala, Fabio
PY - 2007
Y1 - 2007
N2 - Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.
AB - Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.
KW - Dermatitis, atopic
KW - Desloratadine
KW - Histamine H1 antagonists
UR - http://www.scopus.com/inward/record.url?scp=34247281102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247281102&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:34247281102
VL - 142
SP - 29
EP - 34
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0392-0488
IS - 1
ER -